The FDA approved lirafugratinib in FGFR2+ cholangiocarcinoma and belzutifan plus lenvatinib in advanced ccRCC, and more.
|Videos|October 13, 2017
Dr. Inman Discusses the Role of Chemotherapy in Bladder Cancer
Author(s)Brant Inman, MD
Brant Inman, MD, surgical oncologist, urologic oncologist, Duke Cancer Center, discusses the role of chemotherapy in bladder cancer.
Advertisement
Brant Inman, MD, surgical oncologist, urologic oncologist, Duke Cancer Center, discusses the role of chemotherapy in bladder cancer.
Although there have been many trials with chemotherapy combinations, there has not been much progress seen beyond gemcitabine plus cisplatin or with the combination of methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC), says Inman.
Advertisement
Related to this article
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
The FDA has approved belzutifan (Welireg) plus lenvatinib (Lenvima) for use in patients with advanced renal cell carcinoma with a clear cell component after PD-1 or PD-L1 inhibition.
Advertisement
Advertisement
Trending on OncLive
1
Ifinatamab Deruxtecan BLA Voluntarily Withdrawn in Previously Treated Extensive-Stage SCLC
2
FDA Approves Lirafugratinib for Pretreated, Locally Advanced or Metastatic Cholangiocarcinoma
3
FDA Grants Priority Review to Perioperative Durvalumab Plus Neoadjuvant Enfortumab Vedotin in MIBC
4
FDA Approves Belzutifan Plus Lenvatinib for Advanced ccRCC
5